Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT07875959
Recruiting
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
Not applicable · China · 1 site
Registry update: 15 Oct 2026
NCT07835035
Recruiting
Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy
Phase 1 · China · 2 sites
Registry update: 22 Sept 2026
NCT07717242
Recruiting
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
Phase 2 · China · 1 site
Registry update: 21 Jul 2026
NCT07728474
Recruiting
LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Not applicable · Israel · 1 site
Registry update: 29 Jul 2026
NCT07726602
Recruiting
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Not applicable · United States · 1 site
Registry update: 14 Aug 2026
NCT07463963
Recruiting
Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled Trial
Not applicable · France · 15 sites
Registry update: 4 Sept 2026
NCT05521698
Recruiting
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
Phase 1 · United States · 6 sites
Registry update: 30 Sept 2026
NCT07660055
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Phase 1 · Australia, Canada, Japan, United States · 5 sites
Registry update: 3 Nov 2026
NCT07671092
Recruiting
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Early phase 1 · Australia, New Zealand, South Africa · 6 sites
Registry update: 13 Oct 2026
NCT07664397
Recruiting
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
Phase 1 · United States · 1 site
Registry update: 1 Oct 2026
NCT07309445
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Not applicable · United States · 23 sites
Registry update: 3 Nov 2026
NCT07623369
Recruiting
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · Australia, China · 3 sites
Registry update: 21 Aug 2026
NCT07646847
Recruiting
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Not applicable · United States · 8 sites
Registry update: 28 Oct 2026
NCT07484022
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Phase 1 · United States · 10 sites
Registry update: 13 Oct 2026
NCT07898033
Recruiting
1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors
Phase 3 · Israel · 1 site
Registry update: 27 Oct 2026
NCT07524426
Recruiting
Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment
Not applicable · Sweden · 1 site
Registry update: 9 Jun 2026
NCT07870577
Recruiting
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma
Not applicable · Germany · 3 sites
Registry update: 13 Oct 2026
NCT05321316
Recruiting
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Not applicable · China · 1 site
Registry update: 4 Mar 2026
NCT07625527
Recruiting
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Phase 2 · China · 4 sites
Registry update: 15 Oct 2026
NCT07480356
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
Phase 3 · Ukraine, United States · 11 sites
Registry update: 6 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.